Ligand Pharmaceuticals

Ligand Pharmaceuticals is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company's business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Ligand's goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. The Company's business model is based on doing what Ligand does best: drug discovery, early-stage drug development, product reformulation and partnering. 
The Company's technology CAPTISOL is a formulation technology that has enabled seven United States Food and Drug Administration (FDA) approved products including Kyprolis and Noxafil-IV and is being developed in several clinical-stage partner programs. The Company is engaged in the development of product candidates indicated for the treatment of diseases, such as hepatitis, multiple myeloma, muscle wasting, Alzheimer’s disease, dyslipidemia, diabetes, anemia, epilepsy, focal segmental glomerulosclerosis (FSGS) and osteoporosis.

Company Growth (employees)
Type
Public
HQ
San Diego, US
Size (employees)
22 (est)
Website
ligand.com
Ligand Pharmaceuticals is headquartered in San Diego, US

Key People at Ligand Pharmaceuticals

John L. Higgins

John L. Higgins

CEO

Ligand Pharmaceuticals Office Locations

Ligand Pharmaceuticals has an office in San Diego
San Diego, US (HQ)
3911 Sorrento Valley Blvd

Ligand Pharmaceuticals Data and Metrics

Ligand Pharmaceuticals Financial Metrics

Ligand Pharmaceuticals's revenue was reported to be $29.3 m in Q1, 2017
USD

Revenue (Q1, 2017)

29.3 m

Gross profit (Q1, 2017)

28.9 m

Gross profit margin (Q1, 2017), %

99%

Net income (Q1, 2017)

5.1 m

EBIT (Q1, 2017)

10.2 m

Market capitalization (22-Aug-2017)

3 b

Cash (31-Mar-2017)

10.6 m
Ligand Pharmaceuticals's current market capitalization is $3 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

49 m64.5 m71.9 m109 m

Revenue growth, %

32%11%52%

Cost of goods sold

5.6 m

Gross profit

103.4 m

Gross profit Margin, %

95%

R&D expense

21.2 m

General and administrative expense

26.6 m

Operating expense total

47.8 m

EBIT

14.9 m19.6 m27.3 m(2.4 m)

EBIT margin, %

31%30%38%(2%)

Interest expense

2.1 m4.9 m11.8 m12.2 m

Income tax expense

(10.3 m)

Net Income

11.4 m10.9 m254.9 m(1.6 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

10.6 m15 m14.6 m18.4 m17.7 m29.6 m19.5 m21.6 m29.3 m

Cost of goods sold

1.2 m1.5 m1.1 m955 k720 k999 k341 k

Gross profit

9.4 m13.5 m13.5 m28.7 m18.8 m20.6 m28.9 m

Gross profit Margin, %

89%90%93%97%96%95%99%

R&D expense

2.7 m3 m4 m4 m2.5 m4 m4.5 m5.9 m8.7 m

General and administrative expense

5.2 m6.7 m6 m7.2 m5 m6.8 m6.9 m6.3 m7.3 m

Operating expense total

7.9 m9.8 m10 m11.2 m7.5 m10.8 m11.4 m12.2 m16 m

EBIT

1.4 m3.5 m3.3 m4.4 m8.6 m5.9 m4.4 m5.5 m10.2 m

EBIT margin, %

13%24%23%24%49%20%22%25%35%

Interest expense

181 k1.5 m3 m3 m2.9 m3 m3.1 m3.1 m2.9 m

Pre tax profit

1.2 m901 k(74 k)22.3 m7.3 m9.6 m(9.6 m)1.2 m6.2 m

Income tax expense

47 k(124 k)(15 k)(265 k)217.3 m(3.7 m)3.9 m(160 k)(1.1 m)

Net Income

1.3 m1.3 m754 k23.6 m224.5 m6.6 m(5.8 m)505.1 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

11.6 m160.2 m97.4 m18.8 m

Accounts Receivable

2.2 m12.6 m6.2 m14.7 m

Inventories

1.4 m269 k1.6 m1.9 m

Current Assets

24.9 m185.2 m215.6 m163.1 m

PP&E

867 k486 k372 k1.8 m

Goodwill

12.2 m12.2 m12.2 m72.2 m

Total Assets

104.7 m258 m533.9 m601.6 m

Accounts Payable

4 m7.7 m4.1 m2.7 m

Current Liabilities

28.9 m22.8 m20.8 m227.1 m

Total Liabilities

230.7 m

Additional Paid-in Capital

718 m680.7 m701.5 m769.7 m

Retained Earnings

(671.3 m)(659.3 m)(402 m)(431.1 m)

Total Equity

24.4 m304.4 m341.3 m

Financial Leverage

10.6 x1.8 x1.8 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

14.5 m180.7 m165.8 m108.2 m93.8 m31.3 m61.4 m86.6 m10.6 m

Accounts Receivable

3.1 m5.8 m7.4 m5.5 m5.5 m11.8 m10 m6.6 m7.1 m

Inventories

817 k1.1 m2.8 m802 k1.2 m1.8 m3.8 m4 m7.6 m

Current Assets

28.6 m198.5 m191.7 m196.7 m210.3 m133.1 m126.6 m140.7 m174.7 m

PP&E

619 k551 k440 k405 k355 k567 k1.2 m1.8 m1.9 m

Goodwill

12.2 m12.2 m12.2 m12.2 m12.2 m73 m72.4 m72.4 m72.2 m

Total Assets

99.8 m272.3 m263.2 m304.8 m521.7 m613.4 m616.8 m600.9 m629.7 m

Accounts Payable

5.1 m4.9 m7.4 m2.7 m3.1 m2.7 m2.3 m2.8 m6.5 m

Current Liabilities

18.6 m18.4 m18.2 m17.9 m16.3 m12.2 m220.3 m226.1 m227 m

Additional Paid-in Capital

726.8 m707.2 m684.4 m692.8 m697.1 m783.9 m789.3 m762.6 m777.1 m

Retained Earnings

(667.7 m)(666.4 m)(658.6 m)(635 m)(410.5 m)(395.4 m)(401.2 m)(428 m)(408.4 m)

Total Equity

371.8 m

Financial Leverage

1.7 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

11.4 m10.9 m254.9 m(1.6 m)

Depreciation and Amortization

2.7 m2.7 m2.6 m10.6 m

Accounts Receivable

2.4 m(10 m)6.5 m(8.5 m)

Inventories

646 k4.4 m(401 k)(244 k)

Cash From Operating Activities

20.7 m20.6 m41.7 m63 m

Purchases of PP&E

(6 k)(93 k)(1.9 m)

Cash From Investing Activities

(5 m)(2 m)(112.9 m)(143.2 m)

Long-term Borrowings

(19.6 m)(9.4 m)

Cash From Financing Activities

(16.5 m)130 m8.4 m1.5 m

Interest Paid

1.8 m494 k1.8 m1.8 m

Income Taxes Paid

26 k18 k28 k38 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

1.3 m1.3 m754 k23.6 m224.5 m6.6 m(5.8 m)505.1 m

Depreciation and Amortization

2.5 m2.7 m2.7 m2.7 m

Accounts Receivable

3.1 m5.8 m7.4 m5.5 m5.5 m11.8 m10 m6.6 m7.1 m

Inventories

817 k1.1 m2.8 m802 k1.2 m1.8 m3.8 m4 m7.6 m

Accounts Payable

5.1 m4.9 m7.4 m2.7 m3.1 m2.7 m2.3 m2.8 m6.5 m
USDY, 2017

Revenue/Employee

1.3 m

Financial Leverage

1.7 x

Ligand Pharmaceuticals Market Value History

Traffic Overview of Ligand Pharmaceuticals

Ligand Pharmaceuticals Online and Social Media Presence

Ligand Pharmaceuticals Company Life and Culture

You may also be interested in